Everist Genomics Announces External Validation Of OncoDefender™-CRC Test For Predicting Recurrence Risk For Stage I And II Colorectal Cancer Pat

Sunday, January 23rd, 2011

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with ...

Sequenom CMM Commences Pivotal Clinical Validation Study For Its SensiGene Trisomy 21 Laboratory Developed Test

Wednesday, December 29th, 2010

Sequenom, Inc. (Nasdaq: SQNM) announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of ...

Health Discovery Corporation Inks Deal For Final Validation Of A New Molecular Diagnostic Test For Colon Cancer

Friday, February 12th, 2010

Health Discovery Corporation (OTCBB: HDVY) announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of ...